Dement Neurocogn Disord.
2022 Apr;21(2):45-58. 10.12779/dnd.2022.21.2.45.
Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
- Park KH
1 - Jang JW2
- Suh J3
- Yi S4
- Bae JS5
- Lim JS6
- Lee H1
- Chin J7
- Park YH8
- Hong YJ9
- Kim GH10
- on behalf of Academic Committee of the Korean Dementia Association
- Affiliations
-
- 1Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- 2Department of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea
- 3Department of Neurology, National Medical Center, Seoul, Korea
- 4Department of Neurology, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea
- 5Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea
- 6Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 7Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 8Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 9Department of Neurology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea
- 10Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
- KMID: 2529457
- DOI: http://doi.org/10.12779/dnd.2022.21.2.45
Abstract
- Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Executive Summary of 2023 International Conference of the Korean Dementia Association (IC-KDA 2023): A Report From the Academic Committee of the Korean Dementia Association
- Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association
- Subtypes of Vascular Dementia
- Temporal Variant of Frontotemporal Dementia: A Case of Semantic Dementia
- cognitive functions in questionable dementia and non-dementia
